CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services
Provided By GlobeNewswire
Last update: Mar 19, 2025
Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML
SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company’s upcoming Phase 1 clinical trial for Acute Myeloid Leukemia (AML). The Company believes it is on track for dosing the first patient in the first half of 2025.
Read more at globenewswire.com0.8901
-0.22 (-19.81%)
Find more stocks in the Stock Screener
CERO Latest News and Analysis
2 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
2 days ago - ChartmillTop stock movements in today's session.Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.
3 days ago - ChartmillThursday's session: top gainers and losersHere are the top movers in Thursday's session, showcasing the stocks with significant price changes.
3 days ago - ChartmillKeep an eye on the top gainers and losers in Thursday's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
3 days ago - ChartmillWhich stocks are gapping on Thursday?In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.
